Covers compounds researched for melanocortin receptor-mediated sexual arousal, HPG axis modulation, and gonadotropin release as investigated in clinical and preclinical research.
| Compound | Class | Primary Mechanism | Commonly Reported For | Link |
|---|---|---|---|---|
| PT-141 | Melanocortin agonist (MC3R/MC4R) | CNS-mediated arousal via melanocortin receptors; not vascular pathway | Libido, sexual arousal, FDA-approved (Vyleesi) | View profile → |
| Melanotan II | Cyclic melanocortin peptide | Broad melanocortin receptor agonism (MC1R–MC4R); tanning + libido | Tanning, libido, spontaneous arousal | View profile → |
| Kisspeptin | KISS1 neuropeptide | HPG axis activation via GnRH pulse stimulation; LH/FSH surge | Hormonal support, libido, fertility research | View profile → |
Sexual function research at the peptide level converges on two largely distinct axes: the central melanocortin system and the hypothalamic-pituitary-gonadal (HPG) axis. The melanocortin system — particularly MC3R and MC4R receptors in the hypothalamus and limbic regions — has been identified as a key mediator of sexual arousal independently of vascular mechanisms. This distinction is clinically significant: compounds acting via melanocortin receptors can produce arousal responses even in individuals where vascular PDE5 pathways are intact but central drive is impaired. Research in both animal models and human trials has supported this central mechanism, culminating in regulatory review and eventual FDA approval of PT-141 (bremelanotide) for hypoactive sexual desire disorder in premenopausal women.
PT-141 (bremelanotide) reached FDA approval as Vyleesi in 2019 for female sexual arousal disorder and hypoactive sexual desire disorder. Clinical trials demonstrated statistically significant improvements in desire and reductions in distress associated with low libido compared to placebo. The compound's mechanism is strictly central: it does not act on penile or clitoral vasculature but instead modulates dopaminergic and noradrenergic tone downstream of MC4R activation, generating arousal through CNS pathways. Reported side effects in research and anecdotal accounts include transient nausea, flushing, and hyperpigmentation with repeat administration — the latter a consequence of non-selective melanocortin receptor engagement.
Kisspeptin occupies a different position in this research landscape. Rather than acting directly on arousal pathways, kisspeptin neurons in the hypothalamus serve as the master regulator of GnRH pulsatility. Stimulation of kisspeptin receptors drives coordinated GnRH release, which in turn governs pituitary LH and FSH secretion — and thus downstream sex hormone production. Research has investigated kisspeptin administration as a means of restoring or amplifying hormonal signalling in states of HPG axis suppression. Its role in libido is therefore largely indirect: by supporting testosterone and oestrogen levels, it may influence sexual desire through hormonal normalisation rather than acute central arousal.
PT-141 is the only compound in this category with FDA approval, marketed as Vyleesi for FSAD/HSDD in premenopausal women. Research has investigated both intranasal and subcutaneous administration routes; the approved formulation is subcutaneous auto-injector. Its mechanism operates entirely through CNS melanocortin receptors (MC3R/MC4R), with no direct vascular action — differentiating it from PDE5 inhibitors. Reported side effects in research and anecdotal accounts include nausea (the most common), facial flushing, and transient blood pressure elevation. Hyperpigmentation has been noted with repeated use. Commonly reported doses range from 1 mg to 1.75 mg subcutaneously administered approximately 45 minutes prior to activity.
Melanotan II is a cyclic analogue of alpha-MSH with broader receptor binding than PT-141, engaging MC1R through MC4R. This broader agonism produces both the pigmentation response (via MC1R in melanocytes) and central arousal effects (via MC3R/MC4R). It has not received regulatory approval and is not licensed for human use in any jurisdiction. Anecdotal reports suggest spontaneous and prolonged arousal responses, attributed to sustained or non-selective receptor engagement. Reported side effects in research and anecdotal accounts include nausea, facial flushing, spontaneous erections, and darkening of existing moles or nevi. Commonly reported doses range from 0.25 mg to 1 mg subcutaneously for research contexts.
Kisspeptin is a neuropeptide family encoded by the KISS1 gene, with multiple isoforms (kisspeptin-10, -13, -54) differing in length but sharing the C-terminal active region. Research has primarily used intravenous or subcutaneous administration to assess HPG axis response — specifically LH surge amplitude and GnRH pulsatility. Its relevance to libido is upstream and hormonal rather than immediate and arousal-directed: by stimulating GnRH release, kisspeptin research explores restoration of testosterone or oestrogen signalling in individuals with suppressed axis function. Clinical research has also investigated kisspeptin in fertility contexts, including ovulation induction. The distinction between fertility-focused and libido-focused applications is methodologically important when reviewing the literature.
No well-documented combination protocols have emerged for this goal area. Compounds in the libido and sexual function category act via distinct, non-overlapping mechanisms — central melanocortin agonism (PT-141, Melanotan II) versus upstream HPG axis modulation (Kisspeptin) — and are typically researched independently in clinical and preclinical settings. Combination data between these compounds is absent from published literature.
PDE5 inhibitors act peripherally by blocking the breakdown of cGMP in vascular smooth muscle, increasing blood flow to erectile or clitoral tissue. PT-141 operates centrally: it activates MC3R and MC4R receptors in the hypothalamus and limbic system, modulating dopaminergic and noradrenergic tone to generate arousal at the neurological level. This means PT-141 can produce arousal responses independent of vascular status, and conversely, does not require sexual stimulation to exert peripheral vascular effect — the response originates in the CNS rather than locally.
PT-141 (bremelanotide) is a metabolite of Melanotan II and binds primarily to MC3R and MC4R with relatively higher selectivity. Melanotan II engages the full melanocortin receptor family — MC1R through MC4R — producing both skin pigmentation (via MC1R in melanocytes) and central arousal effects (via MC3R/MC4R). This broader agonism is associated with more pronounced pigmentation responses and, anecdotally, more sustained or intense arousal effects, but also a wider side effect profile. PT-141 was developed specifically to capture the arousal mechanism while reducing tanning-related receptor engagement.
The available evidence positions kisspeptin's influence on libido as primarily indirect. Kisspeptin stimulates GnRH pulsatility, which drives pituitary LH and FSH secretion, which in turn regulates gonadal production of testosterone and oestrogen. These sex hormones then exert effects on central arousal pathways, mood, and sexual motivation over a longer time horizon. Research has not established acute, direct kisspeptin-to-libido signalling comparable to the rapid CNS arousal produced by PT-141. The distinction between kisspeptin's hormonal and fertility research applications versus libido outcomes should be considered when evaluating published studies.
PT-141 received FDA approval as Vyleesi (bremelanotide) in 2019 for the treatment of hypoactive sexual desire disorder (HSDD) in premenopausal women. Approval was based on two Phase 3 randomised controlled trials demonstrating statistically significant improvements in desire scores and reductions in distress. In a research context, this means PT-141 has a published clinical efficacy and safety dataset supporting its mechanism, dose range, and side effect profile in human subjects — a level of evidence not available for Melanotan II or the majority of peptides in this category. Researchers reviewing the literature can draw on peer-reviewed trial data rather than relying solely on preclinical or anecdotal sources.